Renata PLC, a leading pharmaceutical manufacturer in Bangladesh, has launched a generic version of Cabergoline 0.5 mg, used to treat hyperprolactinemia and Parkinson’s disease, in Australia under the brand name Dostamine. The first shipment has arrived, and the product will be distributed through Nova Pharmaceuticals Australasia Pty Ltd. This marks the first generic Cabergoline available in Australia, with manufacturing taking place at Renata’s Mirpur factory, which is approved by Australia’s Therapeutic Goods Administration and the UK Medicines and Healthcare Products Regulatory Agency. Renata has also secured approvals for Cabergoline in the UK and the European Union. The global market for Cabergoline is significant, driven by its effectiveness in treating these conditions. In Bangladesh, it is marketed as Cabolin. Renata highlighted this milestone as a reflection of its commitment to expanding product offerings in Australia and New Zealand and its expertise in complex pharmaceuticals.
Source for more details:
